SOM Biotech at World Orphan Drug Congress USA 2017

posted on June 27, 2017
SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA on April 19th-21st. More than 1,000 global attendees did not want to miss the opportunity to discuss the latest trends on Orphan Drugs, a $140Billion dollar market. Topics like pricing, reimbursement, M&A, commercialization, FDA’s considerations, scientific innovation, regional market analysis…
continue reading →

SOM Biotech at BIO Convention 2017

posted on June 13, 2017
SOM Biotech attended last BIO Convention on June 19th-22nd 2017 in San Diego, CA. Michael Greenberg, VP of Business Development, was in attendance. He had the opportunity to discuss potential partnerships on CNS or Orphan Drugs space with several biotech/pharma companies. If you are interested in hearing about SOM’s latest developments, please contact our Business…
continue reading →

SOM Biotech stands for Responsible Innovation

posted on June 7, 2017
SOM Biotech is one of the European companies participating in the EU Compass program, Biomedicine field. COMPASS is an EU-funded project that supports Small and Medium-sized Enterprises (SMEs) in three emerging technology industries in order to manage their research, development and innovation activities in a responsible and inclusive manner. Dr. Esteva, SOM’s Operations Manager, takes part…
continue reading →

SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.

posted on May 23, 2017
SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of Transthyretin Amyloidosis (ATTR).…
continue reading →

SOM Biotech SL Announces New Logo and Website Launch

posted on April 19, 2017
The new and completely redesigned website offers quick and easy access to essential and relevant information on SOM Biotech. This renewed design is aligned with the ambitious stage SOM Biotech is currently entering. After closing a successful €2M round and with its first large program out licensed (SOM0226 for TTR Amyloidosis), SOM Biotech is going…
continue reading →


posted on March 20, 2017
SOM Biotech will attend next BIO-Europe Spring, Europe's largest springtime partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Barcelona from 20 to…
continue reading →